PoC Study of OBE022 in Threatened Preterm Labour (PROLONG)
A Phase 2a, Double-blind, Parallel Group, Randomised, Placebo Controlled, Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of OBE022 added-on to Atosiban, After Oral Administration in Pregnant Women With Threatened Spontaneous Preterm Labour
Sponsor: Cytel Inc.
A PHASE2 clinical study on Preterm Labor, this trial is ongoing. The trial is conducted by Cytel Inc. and has accumulated 12 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jul 2023 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Feb 2023 — Jul 2023 [monthly]
Active Not Recruiting PHASE2
▶ Show 7 earlier versions
-
Sep 2021 — Feb 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Aug 2019 — Jan 2021 [monthly]
Recruiting PHASE2
-
May 2019 — Aug 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — May 2019 [monthly]
Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Dec 2017 — Mar 2018 [monthly]
Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Cytel Inc.
- Iqvia Pty Ltd
- ObsEva SA
- PhinC Development
- Scope International AG
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Balashikha, Russia , Brno, Czechia , Haifa, Israel , Hanoi, Vietnam , Helsinki, Finland , Ho Chi Minh City, Vietnam , Kazan', Russia , Kfar Saba, Israel , Madrid, Spain , Moscow, Russia and 5 more locations